Al-Marrawi, M. Y., Saroya, B. S., Brennan, M. C., Yang, Z., Dykes, T. M., & El-Deiry, W. S. (2013). Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Landes Bioscience.
Citação norma ChicagoAl-Marrawi, Mhd Yaser, Bikramajit Singh Saroya, Matthew C. Brennan, Zhaohai Yang, Thomas M. Dykes, and Wafik S. El-Deiry. Off-label Use of Cetuximab Plus Sorafenib and Panitumumab Plus Regorafenib to Personalize Therapy for a Patient With V600E BRAF-mutant Metastatic Colon Cancer. Landes Bioscience, 2013.
ציטוט MLAAl-Marrawi, Mhd Yaser, et al. Off-label Use of Cetuximab Plus Sorafenib and Panitumumab Plus Regorafenib to Personalize Therapy for a Patient With V600E BRAF-mutant Metastatic Colon Cancer. Landes Bioscience, 2013.